Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Melanoma Research|March 30, 2020
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanomaBożena Cybulska-Stopa, Paweł Rogala, Anna M Czarnecka, et al.
Cancers|January 11, 2022
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive MelanomaAnna M Czarnecka, Krzysztof Ostaszewski, Aneta Borkowska, et al.
Current Oncology (Toronto, Ont.)|February 23, 2024
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal MelanomaKamil J Synoradzki, Natalia Paduszyńska, Malgorzata Solnik, et al.
Cancers|October 29, 2020
Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern ImmunotherapyPawel Teterycz, Anna M Czarnecka, Alice Indini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 19, 2024
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanomaAnna M Czarnecka, Krzysztof Ostaszewski, Piotr Błoński, et al.
Melanoma Research|November 9, 2020
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patientsBożena Cybulska-Stopa, Marcin Ziętek, Grażyna Kamińska-Winciorek, et al.
Targeted Oncology|June 24, 2025
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SDAnna M Czarnecka, Paweł Teterycz, Krzysztof Ostaszewski, et al.
Targeted Oncology|March 11, 2023
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated MelanomaKarolina Piejko, Bożena Cybulska-Stopa, Marcin Ziętek, et al.
The Journal of Dermatological Treatment|May 31, 2021
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanomaBożena Cybulska-Stopa, Marcin Ziętek, Anna M Czarnecka, et al.
Melanoma Research|May 22, 2018
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitorsPaweł Teterycz, Paulina Jagodzińska-Mucha, Bożena Cybulska-Stopa, et al.
Pageof 18